GUTS (Fractyl Health) Total Operating Expense: $92.88 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

GUTS Fractyl Health Inc GUTS
11 GF Score
Price $0.70
! 2 Warning Signs
View Full Analysis

What is Fractyl Health Total Operating Expense?

Fractyl Health GUTS +1.15% 11 Total Operating Expense is $92.88 Mil as of Mar. 2026. GuruFocus rates GUTS with a GF Score™ of 11/100. The stock has 2 warning signs investors should review.

Fractyl Health's Total Operating Expense for the three months ended in Mar. 2026 was $20.82 Mil. Fractyl Health's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was $92.88 Mil.

Fractyl Health Total Operating Expense Related Terms

Fractyl Health Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Fractyl Health's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fractyl Health Total Operating Expense Chart

Fractyl Health Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Operating Expense
Get a 7-Day Free Trial 36.93 49.39 50.88 93.57 96.82

Fractyl Health Quarterly Data
Sep20 Dec20 Jun21 Sep21 Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 24.76 26.08 22.69 23.28 20.82
GUTS
11GF Score
Fractyl Health Inc GUTS
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Fractyl Health Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $92.88 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of $92.88 Mil mean?
Fractyl Health (GUTS) has a Total Operating Expense of $92.88 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Fractyl Health and its competitors.
Is Fractyl Health's Total Operating Expense too high?
Fractyl Health's current Total Operating Expense is $92.88 Mil. Overall, Fractyl Health has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Fractyl Health's Total Operating Expense compare to ENGN and ANIX?
Fractyl Health's Total Operating Expense of $92.88 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Fractyl Health and its competitors. Fractyl Health's current Total Operating Expense is $92.88 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fractyl Health stock overvalued right now?
Fractyl Health (GUTS) has a current Total Operating Expense of $92.88 Mil. The current Total Operating Expense is $92.88 Mil. Fractyl Health's overall GF Score™ is 11/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Fractyl Health (GUTS), the current Total Operating Expense is $92.88 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Fractyl Health Business Description

Address 3 Van de Graaff Drive, Suite 200, Burlington, MA, USA, 01803
Fractyl Health Inc is a clinical stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D). Its Revita and Rejuva candidates are designed to target root causes of metabolic diseases, allowing the company to advance metabolic disease treatment from chronic management towards prevention and reversion of the disease. The Revita DMR System (Revita), its lead product candidate, is based on its insights surrounding the potential role of the gut in obesity.
11GF Score

Get the complete analysis for GUTS

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.70
Price